Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 506

1.

Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.

Camara-Lemarroy CR, Castilló J, Sastre-Garriga J, Tintore M, Montalban X.

Mult Scler. 2018 Feb 1:1352458518761185. doi: 10.1177/1352458518761185. [Epub ahead of print]

PMID:
29473796
2.

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Comabella M, Montalban X.

Brain. 2018 Feb 16. doi: 10.1093/brain/awy006. [Epub ahead of print]

PMID:
29462277
3.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Feb 14. doi: 10.1093/brain/awy021. [Epub ahead of print]

PMID:
29452342
4.

Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis.

Pareto D, Sastre-Garriga J, Alonso J, Galán I, Arévalo MJ, Renom M, Montalban X, Rovira À.

J Neuroimaging. 2018 Feb 5. doi: 10.1111/jon.12500. [Epub ahead of print]

PMID:
29400912
5.

Quantitative spinal cord MRI in radiologically isolated syndrome.

Alcaide-Leon P, Cybulsky K, Sankar S, Casserly C, Leung G, Hohol M, Selchen D, Montalban X, Bharatha A, Oh J.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e436. doi: 10.1212/NXI.0000000000000436. eCollection 2018 Mar.

6.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
7.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
8.

Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

Aymerich FX, Auger C, Alonso J, Alberich M, Sastre-Garriga J, Tintoré M, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2018 Feb;39(2):399-404. doi: 10.3174/ajnr.A5495. Epub 2017 Dec 28.

PMID:
29284602
9.

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.

PMID:
29275979
10.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
11.

[Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].

Midaglia L, Mora L, Mulero P, Sastre-Garriga J, Montalban X.

Rev Neurol. 2018 Jan 1;66(1):25-32. Review. Spanish.

12.

Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.

Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C.

Autoimmun Rev. 2018 Feb;17(2):165-174. doi: 10.1016/j.autrev.2017.11.019. Epub 2017 Nov 28. Review.

PMID:
29191793
13.

Correction to: Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, Sainz de la Maza S, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):32. doi: 10.1007/s00415-017-8679-5.

PMID:
29177546
14.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137. [Epub ahead of print]

15.

Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system.

Matute-Blanch C, Montalban X, Comabella M.

Handb Clin Neurol. 2017;146:67-84. doi: 10.1016/B978-0-12-804279-3.00005-8.

PMID:
29110780
16.

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Arrambide G, Tintore M, Auger C, Río J, Castilló J, Vidal-Jordana A, Galán I, Nos C, Comabella M, Mitjana R, Mulero P, de Barros A, Rodríguez-Acevedo B, Midaglia L, Sastre-Garriga J, Rovira A, Montalban X.

Neurology. 2017 Dec 5;89(23):2351-2356. doi: 10.1212/WNL.0000000000004715. Epub 2017 Nov 3.

17.

The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No.

Tintoré M, Montalban X.

Mult Scler. 2018 Feb;24(2):123-125. doi: 10.1177/1352458517729451. Epub 2017 Oct 23. No abstract available.

PMID:
29059000
18.

Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis.

Martínez-Barriocanal Á, Arcas-García A, Magallon-Lorenz M, Ejarque-Ortíz A, Negro-Demontel ML, Comas-Casellas E, Schwartz S Jr, Malhotra S, Montalban X, Peluffo H, Martín M, Comabella M, Sayós J.

Sci Rep. 2017 Oct 19;7(1):13544. doi: 10.1038/s41598-017-12881-8.

19.

Progressive MS trials: Lessons learned.

Tur C, Montalban X.

Mult Scler. 2017 Oct;23(12):1583-1592. doi: 10.1177/1352458517729460.

PMID:
29041872
20.

Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines.

Miquel-Serra L, Duarri A, Muñoz Y, Kuebler B, Aran B, Costa C, Martí M, Comabella M, Malhotra S, Montalban X, Veiga A, Raya A.

Stem Cell Res. 2017 Oct;24:155-159. doi: 10.1016/j.scr.2017.06.001. Epub 2017 Jun 7.

21.

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

Alenda R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, Rodríguez-Martín E, de la Maza SS, Villarrubia N, Río J, Domínguez-Mozo MI, Montalban X, Álvarez-Cermeño JC, Villar LM.

J Neurol. 2018 Jan;265(1):24-31. doi: 10.1007/s00415-017-8625-6. Epub 2017 Oct 12. Erratum in: J Neurol. 2017 Nov 24;:.

PMID:
29027004
22.

Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates.

Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, Sastre-Garriga J, Romero-Pinel L, Martínez-Yélamos S, Sola-Valls N, Armangué T, Sotoca J, Escartín A, Robles-Cedeño R, Ramió-Torrentà L, Presas-Rodríguez S, Ramo-Tello C, Munteis E, Pelayo R, Gubieras L, Brieva L, Ortiz N, Hervás M, Mañé-Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A.

Mult Scler. 2017 Oct 1:1352458517735191. doi: 10.1177/1352458517735191. [Epub ahead of print]

PMID:
28984163
23.

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, Nestorov I, Chen Y, Dong Q, Ho PR, Amarante D, Adams A, De Sèze J, Fox R, Gold R, Jeffery D, Kappos L, Montalban X, Weinstock-Guttman B, Hartung HP, Cree BAC.

Neurology. 2017 Oct 10;89(15):1584-1593. doi: 10.1212/WNL.0000000000004485. Epub 2017 Sep 15.

24.

Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education.

Saposnik G, Maurino J, Sempere AP, Terzaghi MA, Ruff CC, Mamdani M, Tobler PN, Montalban X.

Front Neurol. 2017 Aug 21;8:430. doi: 10.3389/fneur.2017.00430. eCollection 2017.

25.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2017 Aug 1:1352458517726657. doi: 10.1177/1352458517726657. [Epub ahead of print]

PMID:
28847219
26.

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.

Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):316-318. doi: 10.1136/jnnp-2017-315863. Epub 2017 Jul 19. No abstract available.

PMID:
28724720
27.

Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.

Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.

Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22.

PMID:
28681388
28.

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH; 2016 ECTRIMS Focused Workshop Group.

Mult Scler. 2017 Jan 6:1352458516686847. doi: 10.1177/1352458516686847. [Epub ahead of print]

PMID:
28671487
29.

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

Mulero P, Auger C, Parolin L, Fonseca E, Requena M, Rio J, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2017 Jun 1:1352458517711569. doi: 10.1177/1352458517711569. [Epub ahead of print]

PMID:
28643544
30.

Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis.

Rovira A, Auger C, Huerga E, Corral JF, Mitjana R, Sastre-Garriga J, Tintoré M, Montalban X.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1486-1493. doi: 10.3174/ajnr.A5253. Epub 2017 Jun 15.

PMID:
28619842
31.

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor.

Miralles M, Eixarch H, Tejero M, Costa C, Hirota K, Castaño AR, Puig M, Stockinger G, Montalban X, Bosch A, Espejo C, Chillon M.

Neurotherapeutics. 2017 Oct;14(4):1095-1106. doi: 10.1007/s13311-017-0545-8.

32.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

PMID:
28556498
33.

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

Montalban X, Belachew S, Wolinsky JS.

N Engl J Med. 2017 Apr 27;376(17):1694. doi: 10.1056/NEJMc1702076. No abstract available.

PMID:
28445663
34.

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Vidal-Jordana A, Sastre-Garriga J, Pareto D, Tur C, Arrambide G, Otero-Romero S, Huerga E, Mitjana R, Auger C, Tintoré M, Rovira A, Montalban X.

Mult Scler. 2017 Apr 1:1352458517707070. doi: 10.1177/1352458517707070. [Epub ahead of print]

PMID:
28445084
35.

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Vidal-Jordana A, Montalban X.

Neuroimaging Clin N Am. 2017 May;27(2):195-204. doi: 10.1016/j.nic.2016.12.001. Review.

PMID:
28391781
36.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Arrambide G, Rovira A, Sastre-Garriga J, Tur C, Castilló J, Río J, Vidal-Jordana A, Galán I, Rodríguez-Acevedo B, Midaglia L, Nos C, Mulero P, Arévalo MJ, Comabella M, Huerga E, Auger C, Montalban X, Tintore M.

Mult Scler. 2017 Mar 1:1352458517697830. doi: 10.1177/1352458517697830. [Epub ahead of print]

PMID:
28301287
37.

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus.

Carrillo-Salinas FJ, Mestre L, Mecha M, Feliú A, Del Campo R, Villarrubia N, Espejo C, Montalbán X, Álvarez-Cermeño JC, Villar LM, Guaza C.

Sci Rep. 2017 Mar 14;7:44377. doi: 10.1038/srep44377.

38.

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Río J, Rovira À, Tintoré M, Otero-Romero S, Comabella M, Vidal-Jordana Á, Galán I, Castilló J, Arrambide G, Nos C, Tur C, Pujal B, Auger C, Sastre-Garriga J, Montalban X.

Mult Scler. 2017 Mar 1:1352458517698052. doi: 10.1177/1352458517698052. [Epub ahead of print]

PMID:
28287331
39.

Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation.

Eixarch H, Calvo-Barreiro L, Montalban X, Espejo C.

Brain Behav Immun. 2018 Feb;68:1-10. doi: 10.1016/j.bbi.2017.02.019. Epub 2017 Feb 27. Review.

PMID:
28249802
40.

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials.

Sørensen PS, Comi G, Vollmer TL, Montalban X, Kappos L, Dadon Y, Gorfine T, Margalit M, Sasson N, Rubinchick S, Knappertz V.

Int J MS Care. 2017 Jan-Feb;19(1):16-24. doi: 10.7224/1537-2073.2015-024.

41.

Metabolomic signatures associated with disease severity in multiple sclerosis.

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar.

42.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

43.

Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, Spelman T, Sormani MP, Butzkueven H.

Nat Rev Neurol. 2017 Feb;13(2):105-118. doi: 10.1038/nrneurol.2016.188. Epub 2017 Jan 13. Review.

PMID:
28084327
44.

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

Matute-Blanch C, Río J, Villar LM, Midaglia L, Malhotra S, Álvarez-Cermeño JC, Vidal-Jordana A, Montalban X, Comabella M.

J Neuroimmunol. 2017 Feb 15;303:62-65. doi: 10.1016/j.jneuroim.2016.12.006. Epub 2016 Dec 18.

PMID:
28063616
45.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.

46.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

47.

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP.

Mult Scler Relat Disord. 2016 Nov;10:204-212. doi: 10.1016/j.msard.2016.10.010. Epub 2016 Nov 3.

48.

Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images.

Vidal-Jordana A, Pareto D, Sastre-Garriga J, Auger C, Ciampi E, Montalban X, Rovira A.

AJNR Am J Neuroradiol. 2017 Feb;38(2):250-256. doi: 10.3174/ajnr.A4999. Epub 2016 Nov 24.

49.

Correction: Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

Lopez de Lapuente A, Feliú A, Ugidos N, Mecha M, Mena J, Astobiza I, Riera J, Carrillo-Salinas FJ, Comabella M, Montalban X, Alloza I, Guaza C, Vandenbroeck K.

J Immunol. 2016 Nov 15;197(10):4177. No abstract available.

50.

Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis.

Casacuberta-Serra S, Costa C, Eixarch H, Mansilla MJ, López-Estévez S, Martorell L, Parés M, Montalban X, Espejo C, Barquinero J.

Exp Neurol. 2016 Dec;286:50-60. doi: 10.1016/j.expneurol.2016.09.012. Epub 2016 Sep 28.

PMID:
27693617

Supplemental Content

Loading ...
Support Center